Monitoring measurable residual disease (MRD) via liquid biopsy is a method for catching early-stage cancer and disease relapse before traditional diagnostics, which generally require significant disease progression for detection.
Assays in development include those that target patient-specific variants and fixed panels for all patients. Regardless, detection of variant allele frequencies at extremely low levels, well below the limit of detection of typical circulating tumor DNA (ctDNA) assays, presents a challenge that can be surmounted with well-designed reference materials that allow for assessment of sensitivity and specificity. We developed the Seraseq ctDNA MRD Panel kit composed of four tumor fractions at decreasing levels to meet the validation needs of both patient-specific and fixed panel targeted ccfDNA NGS MRD assays.
This poster from LGC Clinical Diagnostics presents data demonstrating the performance of the Seraseq ctDNA MRD Panel as reference materials for assessing the sensitivity and specificity of patient-specific and fixed-panel liquid biopsy MRD assays.
Offered Free by: LGC SeraCare Life Sciences
See All Resources from: LGC SeraCare Life Sciences